Fundraising FoxGreenwich LifeSciences
Stafford, US · Delaware corporation
Find your way into Greenwich LifeSciences
Sign up to see every warm intro you have to Greenwich LifeSciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Greenwich LifeSciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, a peptide immunotherapy targeting the HER2/neu protein, aimed at preventing breast cancer recurrence. It is running Flamingo-01, a global Phase III trial evaluating its GLSI-100 candidate in HER2/neu positive breast cancer patients.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2024
▶$2.5MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth HallockDirector
- Eric RotheDirector
- F. Joseph DaughertyExecutive Officer, Director
- David McWilliamsDirector
- Snehal PatelExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies working in the same space as Greenwich LifeSciences.
In the news
Frequently asked questions
- What does Greenwich LifeSciences do?
- Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, a peptide immunotherapy targeting the HER2/neu protein, aimed at preventing breast cancer recurrence. It is running Flamingo-01, a global Phase III trial evaluating its GLSI-100 candidate in HER2/neu positive breast cancer patients.
- Who founded Greenwich LifeSciences?
- Greenwich LifeSciences was founded by Snehal Patel.
- How much funding has Greenwich LifeSciences raised?
- Greenwich LifeSciences has disclosed $2.5M raised across 1 round.
- Where is Greenwich LifeSciences headquartered?
- Greenwich LifeSciences is headquartered in Stafford, US.